Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.31 |
| ▸ | PIM1 | P11309 | 4/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955983 | 0.64 | PIK3CG (0.54) | PIK3CGTSHRNTRK1PIM1ALDH1A1 | |
| SCHEMBL10556141 | 0.63 | PIK3CG (1.00) | PIK3CGTSHRNTRK1PIM1ACVR1 | |
| SCHEMBL25680977 | 0.60 | PIK3CG (0.57) | PIK3CGNTRK1PIM1ACVR1ALDH1A1 | |
| SCHEMBL4354498 | 0.58 | ALDH1A1 (0.41) | PIK3CGTSHRNTRK1PIM1ACVR1 | |
| SCHEMBL18578663 | 0.58 | PIK3CG (0.54) | PIK3CGNTRK1PIM1ACVR1ALDH1A1 | |
| SCHEMBL952390 | 0.57 | ALOX12 (0.54) | ALDH1A1LMNATDP1 | |
| SCHEMBL7636742 | 0.56 | LMNA (0.30) | LMNA | |
| SCHEMBL23284547 | 0.55 | PIK3CG (0.37) | PIK3CGTSHRNTRK1PIM1ACVR1 | |
| SCHEMBL1821874 | 0.55 | TSHR (0.47) | PIK3CGTSHRALDH1A1MEN1LMNA | |
| SCHEMBL29196315 | 0.55 | PIK3CG (0.37) | PIK3CGTSHRNTRK1PIM1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | PIK3CG 22/4885TSHR 1608/4885NTRK1 3800/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | PIK3CG 18/4885TSHR 2433/4885NTRK1 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.